FILING ANALYSIS · MONDAY, OCTOBER 26
Nautilus Biotechnology, Inc. NAUT — 8-K: Results of Operations and Financial Condition
neutral
Nautilus Biotechnology reported a net loss of $15.6 million for the third quarter of 2026, with revenue of $0.2 million and operating expenses of $16.9 million, but also announced participation in a research consortium that could bring in up to $6 million in funding, which may be a positive catalyst for the stock, however, the overall financial performance is not significantly better than expected
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →